A Randomized Phase II Trial of Erlotinib Alone or In Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 13 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2016 Planned number of patients changed from 118 to 86.